Globus Medical (GMED) Q2 Revenue Up 18%

Globus Medical (NYSE:GMED), a spinal and musculoskeletal medical device company, reported its Q2 2025 earnings on August 7, 2025. The main highlight was a jump in headline net income (GAAP) in Q2 2025, driven by unique, non-operational items such as a major acquisition gain and a one-time tax benefit. Reported revenue (GAAP) was $745.3 million, surpassing the analyst estimate of $741.1 million. Non-GAAP earnings per share (EPS) landed at $0.86, outpacing the $0.75 estimate. Under the surface, core U.S. Spine business delivered growth of 5.7% (as reported), Enabling Technologies revenue (GAAP) dipped, and adjusted profit margins (non-GAAP, as a percentage of net sales) compressed somewhat. The company reaffirmed its annual guidance for fiscal 2025, projecting revenue in the range of $2.80 to $2.90 billion and non-GAAP fully diluted EPS between $3.00 and $3.30, signaling management’s continued confidence, but did not provide an upward revision following the modest beat this period. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. Globus Medical develops and sells devices for treating musculoskeletal disorders, with a focus on spinal surgeries and orthopedic problems. Its core business includes spinal implants, surgical instruments, robotics, and enabling technologies for navigation and planning.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool